Table 7 Selected relevant pre-clinical assays based on novel drug-loaded polymeric nanoparticles for the treatment of bacterial neuroinfections

Streptococcus pneumonia

Bacitracin A

PLGA

PEG

RGV29

P-gP inhibitor

30 mg/kg

I.v

Kunming mice + S. pneumonia

ATCC49619 and S. pneumonia 16,167

In vivo results further demonstrated that PNPs were able to accumulate in brain parenchyma and exhibited high therapeutic efficiencies in resistant PM mouse models with negligible systemic toxicity

Hong et al. [122]

Pseudomonas aeruginosa

LPS

Acrylamide and N,N´-methylenebisacrylamide

–

5 mg/kg of NPs

I.c.v

Kunming mice + P. aeruginosa

Selective recognition of target bacteria. Significantly strong inhibition of bacterial growth

Long et al. [120]

Neisseria meningitidis

CPS-A

Albumin

–

250 µg of NPs

–

DC2.4 cell line

Surface expression of MHC I, MHC II, CD95 and co-stimulatory molecules in dendritic cells were incremented with CPS-loaded PNPs

Gala et al. [119]